Key result
Pre-stroke CV medications show no association with early hemodynamics or 6-month post-stroke mortality.
Why the study?
Whether pre-stroke cardiovascular treatment is reflected in the early systemic hemodynamic phenotype after acute ischemic stroke was uncertain, prompting evaluation of associations between major medication classes, early impedance-cardiography measures, and 6-month mortality.
Does pre-stroke cardiovascular pharmacotherapy affect early systemic hemodynamics within 24 hours of admission and 6-month mortality in patients with acute ischemic stroke?
Cohort (n=233)
Yes
Does pre-stroke cardiovascular pharmacotherapy affect early systemic hemodynamics within 24 hours of admission and 6-month mortality in patients with acute ischemic stroke?
Documented pre-stroke use of major cardiovascular medication classes is not robustly associated with early systemic hemodynamic parameters or 6-month mortality in patients presenting with acute ischemic stroke.
Answers are grounded in this paper and cite their sources.
Exploratory links between pre-stroke meds and post-AIS hemodynamics warrant validation; leaves open effects on 6-month mortality.
Background/Objectives: Whether pre-stroke cardiovascular treatment is reflected in the early systemic hemodynamic phenotype after acute ischemic stroke (AIS) is uncertain. We examined associations between major medication classes, early impedance-cardiography measures, and 6-month mortality. Methods: This prospective multicenter cohort included 233 patients with AIS and available pre-stroke medication data. Hemodynamics were assessed within 24 h of hospital admission. Four drug–physiology pairs were prespecified: beta-blockers–heart rate, renin–angiotensin system inhibitors–systemic vascular resistance index (SVRI), calcium-channel blockers–SVRI, and loop/thiazide(-like) diuretics–thoracic fluid content (TFC). Because technical equivalence of absolute TFC output between acquisition platforms was not established, inferential TFC analyses were restricted to CardioScreen/Niccomo observations. Primary hemodynamic models used HC3 robust standard errors with Holm correction; mortality models used FDR correction. Results: Mean age was 73.7 ± 12.1 years, 53.2% were women, and median NIHSS was 7 [4–12]. None of the four primary associations was supported after Holm correction. Adjusted differences were +0.23 bpm for beta-blockers–heart rate, +192 dyn·s·cm−5·m2 for RAAS inhibitors–SVRI, +254 dyn·s·cm−5·m2 for calcium-channel blockers–SVRI, and −3.72 1/kΩ for diuretics–TFC in the CardioScreen/Niccomo-restricted analysis (nominal p = 0.013; Holm p = 0.053). No secondary association survived FDR correction (all q ≥ 0.406). Forty-seven of 208 patients (22.6%) died within 6 months; no medication class was independently associated with mortality (all q ≥ 0.711). Conclusions: Documented pre-stroke cardiovascular medication use was not robustly associated with the early systemic hemodynamic phenotype or adjusted 6-month mortality after AIS. Modest class-specific associations cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Gutknecht et al. (2026) conducted a cohort in Acute ischemic stroke (n=233). Pre-stroke cardiovascular medication use (beta-blockers, RAAS inhibitors, calcium-channel blockers, loop/thiazide(-like) diuretics) vs. No pre-stroke use of respective medication class was evaluated on Four prespecified drug–physiology pairs within 24 h of admission (beta-blockers–heart rate, RAAS inhibitors–SVRI, calcium-channel blockers–SVRI, diuretics–TFC) and 6-month mortality (MD -3.72 1/kΩ (diuretics–TFC), p=0.053 (Holm corrected for diuretics–TFC)). Pre-stroke cardiovascular medication use was not associated with early systemic hemodynamics or 6-month mortality after acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: